Research Reports

Macleods Pharmaceuticals Ltd Unlisted Shares

Macleods Pharmaceuticals Ltd company logo

Macleods Pharmaceuticals Ltd Share Price

PHYSICAL

PUBLIC LIMITED

Price Chart

1W
1M
1Y
MAX

High

₹33,000

Low

₹505

Return

-

Buy Sell Macleods Pharmaceuticals Ltd Unlisted Shares

As of May 21, 2026, Macleods Pharmaceuticals Ltd, Unlisted Shares are trading at ₹530.25 per share and face value is ₹1.00/share, with a 52-week high of ₹505.00 and 52-week low of ₹505.00. The minimun lot size is None shares, and the shares are traded on .

ISIN

info icon

INE05JF01026

Face Value

info icon

1

Total Shares

info icon

59,88,20,400

Market Cap

info icon

31,752.45 Cr

Profit After Tax

info icon

1,328.26 Cr

Total Revenue

info icon

8,207.09 Cr

P/E

info icon

23.91

P/B

info icon

7.19

Sector

info icon

Health Care

Sub-sector

info icon

Pharmaceuticals

Category

info icon

Mid Cap

Cashflow - Operations

info icon

1,439.59 Cr

About Macleods Pharmaceuticals Ltd

Company Overview:
  • Macleods Pharmaceuticals is engaged in the development, manufacturing, marketing, and distribution of various formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment.
  • Macleods Pharmaceuticals caters to therapies such as antituberculosis, antimalarials, antiretrovirals, antibacterial, antidiabetics, antihypertensives, and antiasthmatics. The company is also known for the number of WHO-pre qualified medicines, used in the treatment of HIV/AIDS, Malaria, Tuberculosis (TB), and opportunistic infections.
  • The company has the highest number of WHO pre-qualified products globally with 65 registrations, and the highest number of WHO pre-qualified anti-TB product registrations with 32 registrations.
  • Macleods Pharmaceuticals has a strong international presence and exports its products to over 100 countries worldwide. The company has subsidiaries and offices in several countries including the United States, the United Kingdom, Spain, South Africa, Russia, Malaysia, and Ukraine, etc.
  • The company had a portfolio of 595 brands in the Indian Pharmaceutical Market in FY21 with 2 brands in the top 100 Indian brands. The company had successfully scaled new brands in short durations, with the brand Panderm++ crossing ₹ 1 bn in domestic sales. 
  • The company also ranked 1st in the molecular group of Clobetasol, Miconazole, and Neomycin in the Indian Pharmaceutical Market in terms of sales. The company launched new brands Vildamac and Vildamac M in the anti-diabetic market.
  • Macleods Pharma has the state of the art manufacturing facilities that comply with international quality standards. The company has manufacturing units spread across India such as Daman, Baddi, Sikkim, Indore, Palghar, Dahej, and Sarigam.
  • Macleods Pharmaceuticals adheres to regulatory guidelines and complies with regulations set by regulatory authorities in the countries where it operates. This includes compliance with regulatory bodies such as the U.S. Food and Drug Administration (FDA), the Medicines and Healthcare Products. Regulatory Agency (MHRA) in the UK, and others.
  • Macleods Pharmaceuticals was founded in the year 1986 by Dr. R. A. Agarwal along with his two brothers - Girdhari Lal and Banwari Lal. The company got incorporated as a Public Limited company on 5th June in the year 1989 and is the seventh largest pharma company in India with a sales team of more than 4,900 medical representatives.

Want to See a Detailed Investment Analysis?

Explore in-depth financial analysis, performance metrics, and key disclosures.

Macleods Pharmaceuticals Ltd Media

News

Articles

Videos

Macleods Pharma Wins Legal Battle Over Linagliptin Patent

Macleods Pharma Wins Legal Battle Over Linagliptin Patent

20 Jan 2025

Medical Dialogues

Macleods Pharma recalls 10,000 bottles of anti-bacterial medication in US over labeling error

Macleods Pharma recalls 10,000 bottles of anti-bacterial medication in US over labeling error

25 Jan 2023

Live Mint

Macleods Pharmaceuticals' purchases Juhu property for Rs 3.32 billion

Macleods Pharmaceuticals' purchases Juhu property for Rs 3.32 billion

14 Sep 2022

Construction World

Frequently Asked Question (FAQs)

Where can I find the annual report of Macleods Pharmaceuticals Ltd Ltd?

The annual report of Macleods Pharmaceuticals Ltd Ltd is available in the annual report section.

How to buy Macleods Pharmaceuticals Ltd Unlisted Shares?

Please find below the procedure for buying Macleods Pharmaceuticals Ltd Unlisted Shares at Planify.
• 1. You confirm booking of Macleods Pharmaceuticals Ltd Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling Macleods Pharmaceuticals Ltd Unlisted Shares is 6 months after listing. Hence you can’t sell Macleods Pharmaceuticals Ltd Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

What is the lock-in period of Macleods Pharmaceuticals Ltd Unlisted Shares?

Lock-in period of Macleods Pharmaceuticals Ltd Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of Macleods Pharmaceuticals Ltd Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of Macleods Pharmaceuticals Ltd Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

See More

Macleods Pharmaceuticals Ltd

₹ 530.25

cartIcon